Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer

Figures & data

Figure 1. Patient flow-chart.

Table 1. Clinico-pathological characteristics and treatment according to sTils group in the full cohort.

		Tils full cohort N = 411
		sTils
		All	<10%		10–59%		≥60%		ptrend
		N	N	%	N	%	N	%
		411	101	25	197	48	113	27
BRCA status	1	243	38	16	118	49	87	36	<0.0001
	2	168	63	38	79	47	26	15
BRCA test	≥2years	224	55	25	110	49	59	26	0.7
	<2 years	187	46	25	87	47	54	29
Year of diagnosis	<2000	109	25	23	52	48	32	29	0.6
	≥2000	302	76	25	145	48	81	27
Age	18-39	157	33	21	70	45	54	34	0.009
	40-59	214	56	26	105	49	53	25
	≥60	40	12	30	22	55	6	15
Menopausal status	Premenopausal	303	71	24	142	47	90	29	0.1
	Postmenopausal	108	30	28	55	51	23	21
Tumor size	≤10 mm	48	12	25	28	58	8	17	0.4
	11-20 mm	188	40	21	88	47	60	32
	21–50 mm	163	44	26	79	47	43	26
	>50 mm	12	5	42	5	42	2	17
Histology	Ductal	355	91	26	182	51	82	23	0.0002
	Lobular	15	9	60	6	40	0	0	0.0007^a
	Medullary	39	0	0	8	21	31	79	<0.0001^b
	Other	2	1	50	1	50	0	0
Grade	1	29	15	52	13	45	1	3	<0.0001
	2	114	46	40	63	55	5	4
	3	268	40	15	121	45	107	40
Positive lymph nodes	0	223	50	22	100	45	73	33	0.008
	1–3	135	33	24	70	52	32	24
	≥4	53	18	34	27	51	8	15
ER	Positive	219	77	35	113	52	29	13	<0.0001
	Negative	192	24	13	84	44	84	44
PR	Positive	179	66	37	88	49	25	14	<0.0001
	Negative	231	34	15	109	47	88	38
	Unknown	1	1	100	0	0	0	0
HER2	Positive	24	4	17	17	71	3	13	0.3
	Negative	386	96	25	180	47	110	29
	Unknown	1	1	100	0	0	0	0
Surgery	Mastectomy	234	67	29	112	48	55	24	0.01
	Breast conserving surgery	177	34	19	85	48	58	33
Systemic therapy	Chemotherapy alone:	210	37	18	98	47	75	36	0.0002
	Chemotherapy and endocrine therapy:	114	40	35	54	47	20	18
	Endocrine therapy alone:	38	11	29	23	61	4	11
	None:	49	13	27	22	45	14	29
RRCM	No	242	59	24	116	48	67	28	1.00
	Yes	169	42	25	81	48	46	27
RRSO	No	77	23	30	37	48	17	22	0.2
	Yes	334	78	23	160	48	96	29

^a Lobular vs non-lobular.

^b Medullary vs non-medullary.

Figure 2. Distribution of percentage sTils according to BRCA gene.

Table 2. Percentage of BRCA1 and BRCA2 breast cancers with low, intermediate and high sTils percentage.

Tils OS cohort N = 399
		<10%		10–59%		≥60%		ptrend
		n	%	n	%	n	%
	All	96	24	193	48	110	28
BRCA status	1	36	15	118	50	84	35	<0.0001
	2	60	37	75	47	26	16
Tils DFS cohort N = 277
	All	67	24	135	49	75	27
BRCA status	1	25	16	81	50	55	34	<0.0001
	2	42	36	54	47	20	17

Figure 3. Ten-year overall survival (OS) and disease-free survival (DFS) according to sTils groups (high, intermediate and low): OS for BRCA1 (A), OS for BRCA2 (B), DFS for BRCA1 (C) and DFS for BRCA2 (D).

Figure 4. Estimated function of survival with percentage sTils in BRCA1 and BRCA2 breast cancers.